Absci Corporation is a clinical-stage biopharmaceutical company specializing in the development of differentiated antibody therapeutics through an AI-native approach. The company combines generative AI models with high-throughput laboratory validation to design and optimize antibody-based drugs targeting underexplored biological mechanisms. Absci’s platform accelerates drug discovery, reducing development timelines and costs compared to traditional methods, while focusing on areas with significant unmet medical needs.

Absci generates revenue through three primary avenues: advancing internally developed drug candidates, partnering or out-licensing select pipeline assets, and collaborating with third parties to leverage its Integrated Drug Creation platform. Internally developed programs, such as ABS-201 for androgenetic alopecia and endometriosis, are designed to address high-unmet-need indications and may eventually yield commercial product sales. Partnerships and out-licensing arrangements provide non-dilutive capital through upfront fees, research funding, clinical and commercial milestones, and royalties. The company also enters drug creation collaborations with pharmaceutical and biotechnology firms, offering its AI-driven platform to support early-stage discovery efforts.

The company operates through the following segments:

• Internally Developed Programs: This segment focuses on advancing proprietary drug candidates from AI-driven design through clinical development. Absci prioritizes underexplored biological targets in areas such as dermatology, women’s health, and immunology, where existing therapies are inadequate. The lead candidate, ABS-201, targets the prolactin receptor for androgenetic alopecia and endometriosis, with Phase 1/2a trials underway. Additional preclinical programs address oncology and inflammatory diseases, with select assets earmarked for partnerships or out-licensing.

• Partnered Programs: This segment encompasses collaborations with third-party biopharmaceutical companies to apply Absci’s AI-native platform for drug discovery and co-development. Partnerships typically involve upfront payments, research funding, and milestone-based compensation, along with royalties on future product sales. Absci has established partnerships with companies such as Merck, AstraZeneca, and Almirall, leveraging its platform to design novel antibody therapeutics for external pipelines.

Absci occupies a distinctive position within the biopharmaceutical industry by integrating AI with wet-lab validation to create a lab-in-the-loop drug discovery platform. The company’s competitive advantages include its ability to design antibodies against "zero-prior" epitopes—targets lacking pre-existing structural data—using its proprietary Origin-1 model. This capability enables Absci to address difficult-to-drug targets more efficiently than traditional methods, which often rely on lengthy and costly screening processes. Competitors in the AI-driven drug discovery space include Generate Biomedicines and Xaira Therapeutics, while clinical-stage rivals for its lead programs include Hope Medicine and Pelage Pharmaceuticals. Absci’s platform has demonstrated capital efficiency, advancing programs to IND-enabling studies in approximately two years at a cost of $15 million per program, compared to the industry average of 4–6 years and over $50 million.

Absci’s customer base primarily consists of pharmaceutical and biotechnology companies engaged in drug discovery and development partnerships. The company has collaborated with established firms such as Merck, AstraZeneca, and Almirall, providing its AI-driven platform to support their early-stage research. For internally developed programs, Absci’s ultimate customers are patients with conditions such as androgenetic alopecia, endometriosis, and inflammatory bowel disease, where current treatment options are limited or ineffective.